8-K: Atara Biotherapeutics' Tab-cel BLA Granted Priority Review by FDA, Potential First Approval for EBV+ PTLD

The FDA has accepted Atara Biotherapeutics' Biologics License Application for tabelecleucel (tab-cel) with a priority review, setting a target action date of January 15, 2025.

Summary

• Atara Biotherapeutics has announced that the FDA has accepted its Biologics License Application (BLA) for tabelecleucel (tab-cel) for priority review.
• Tab-cel is an allogeneic T-cell immunotherapy designed to target and eliminate Epstein-Barr virus (EBV)-infected cells.
• The BLA is for the treatment of adult and pediatric patients two years of age and older with EBV positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy.
• The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of January 15, 2025.
• If approved, tab-cel would be the first approved therapy in the U.S. for EBV+ PTLD.
• The BLA is supported by data from over 430 patients, including the pivotal ALLELE study which showed a 48.8% Objective Response Rate (ORR).
• The acceptance of the BLA triggers a $20 million milestone payment from Pierre Fabre Laboratories, with an additional $60 million milestone upon FDA approval.

Sentiment

Score: 9

Explanation: The document is highly positive due to the FDA's acceptance of the BLA for priority review, the potential for a first-in-class therapy, and the significant milestone payments. The strong clinical data and existing regulatory approvals in other regions further support a positive outlook.

Positives

• The FDA's priority review designation highlights the high unmet need for EBV+ PTLD treatment.
• Tab-cel has already received marketing authorization in Europe, the UK, and Switzerland under the brand name Ebvallo.
• The partnership with Pierre Fabre Laboratories includes reimbursement for global development costs and inventory purchases.
• Atara is eligible for sales milestones and double-digit tiered royalties on net sales of tab-cel in the U.S. and other global markets.
• The treatment has shown a favorable safety profile consistent with previous analyses.

Negatives

• The document does not explicitly mention any negatives.

Risks

• The approval of tab-cel is not guaranteed, and the FDA may not approve the BLA by the target action date.
• The company's financial performance is subject to risks and uncertainties, including the need for additional capital.
• The COVID-19 pandemic and the wars in Ukraine and the Middle East may impact the company's business, research, and clinical development plans.
• The company's ability to access capital and the value of its common stock are subject to market conditions.

Future Outlook

Atara anticipates a potential launch of tab-cel in the U.S. in early 2025, along with a potential label expansion through the multicohort Phase 2 EBVision trial. The company also expects to transition substantially all activities relating to tab-cel to Pierre Fabre at the time of the BLA transfer.

Management Comments

• Pascal Touchon, President and Chief Executive Officer of Atara, stated that the acceptance of the tab-cel BLA is a significant milestone towards making this first-of-its-kind treatment available to patients in the U.S.
• Pascal Touchon also noted that the FDA's granting of priority review highlights the high unmet need in EBV+ PTLD.

Industry Context

This announcement is significant as it represents a potential first-in-class therapy for EBV+ PTLD, a disease with limited treatment options. The priority review status underscores the FDA's recognition of the unmet medical need in this area. The successful development and approval of tab-cel could position Atara as a leader in T-cell immunotherapy.

Comparison to Industry Standards

• The 48.8% Objective Response Rate (ORR) demonstrated in the ALLELE study is a strong result for a therapy targeting a difficult-to-treat disease like EBV+ PTLD.
• Many other companies are developing cell therapies, but Atara's allogeneic approach, which does not require T-cell receptor or HLA gene editing, is a differentiator.
• Companies like Kite Pharma and Novartis have had success with CAR-T therapies, but these are typically autologous (using the patient's own cells) and not allogeneic (using cells from a donor) like tab-cel.
• The regulatory approvals in Europe, the UK, and Switzerland under the brand name Ebvallo provide a benchmark for the potential success of tab-cel in the U.S.

Related Party Transactions

• The document mentions a partnership with Pierre Fabre Laboratories, including milestone payments, reimbursement for development costs, and sales royalties.

Stakeholder Impact

• Shareholders will likely react positively to the news of the FDA's priority review and the potential for a first-in-class therapy.
• Patients with EBV+ PTLD stand to benefit from a new treatment option.
• Employees of Atara Biotherapeutics may experience increased job security and potential for growth.
• Pierre Fabre Laboratories will benefit from the potential commercial success of tab-cel.

Next Steps

• Atara will continue to work closely with Pierre Fabre Laboratories to prepare for the potential launch of tab-cel in the U.S. in early 2025.
• The company will also pursue a potential label expansion through the multicohort Phase 2 EBVision trial.
• Atara will transition substantially all activities relating to tab-cel to Pierre Fabre at the time of the BLA transfer.

Key Dates

Keywords

tabelecleucel, tab-cel, Atara Biotherapeutics, FDA, BLA, Epstein-Barr virus, EBV+ PTLD, T-cell immunotherapy, Priority Review, Pierre Fabre Laboratories